SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

29 $24 $28 $28 $29 $31 $34 76% 74% 73% 73% 74% 74% 0% 10% 20% 30% 40% 50% 60% 70% 80% $0 $5 $10 $15 $20 $25 $30 $35 $40 2017A 2018E 2019E 2020E 2021E 2022E Sales Gross Margin 2017A - 2022E Net Product Sales • 2018 YTD net sales up 22 % vs. 2017 driven by acceleration of TRx growth and recent gross - to - net favorability • TRx up 6.8 % in Q 3 2018 vs.Q 3 2017 , largely driven by repositioning sales force to focus on Zohydro ® ER with BeadTek ® • For projection period, Zohydro ® ER with BeadTek ® assumed to experience ~ 3 % year - over - year TRx growth and ~ 8 % WAC growth • Zohydro ® ER with BeadTek ® market positioning strengthened on account of its top competitor ceasing active physician marketing efforts in February 2018 • Projections assume settlement with IP litigation counterparties • 2019 includes impact of 20 mg stockout for first six months, plus reduced sales force Note: Projections are subject to numerous assumptions and risks. ($ in millions) Zohydro ® ER with BeadTek ® Forecast A A